Category: Latest News

  • Snowflake Surges to 52-Week High of $209.86 Amid Strong Growth and Analyst Optimism

    Snowflake Surges to 52-Week High of $209.86 Amid Strong Growth and Analyst Optimism

    Shares of Snowflake Inc. (NYSE:SNOW) soared to a 52-week high of $209.86, fueled by robust earnings, upbeat analyst sentiment, and growing confidence in the company’s long-term positioning in cloud data infrastructure. The stock has returned 51% over the past year, supported by year-over-year revenue growth of 27.5%, reaching $3.84 billion. Analysts are increasingly bullish on…

  • CrowdStrike Hits Record High of $474.60 as Wall Street Bets on Continued Cybersecurity Growth

    CrowdStrike Hits Record High of $474.60 as Wall Street Bets on Continued Cybersecurity Growth

    CrowdStrike Holdings Inc. (NASDAQ:CRWD) reached a new all-time high of $474.60, marking a significant milestone for the cybersecurity giant as investor enthusiasm continues to build. The stock has climbed 50.3% over the past year, driven by the company’s strong financial performance, expanding market presence, and momentum in next-gen cybersecurity technologies. With a market capitalization of…

  • Robinhood Hits 52-Week High of $67.13 Amid Product Expansion and Crypto Growth

    Robinhood Hits 52-Week High of $67.13 Amid Product Expansion and Crypto Growth

    Robinhood Markets Inc. (NASDAQ:HOOD) surged to a 52-week high of $67.13, with shares recently trading at $66.78. The stock has now delivered a remarkable 216.51% return over the past year, reflecting a major rebound in investor sentiment and confidence in the company’s evolving business model. With a market capitalization of $59.56 billion and a price-to-earnings…

  • Kymera Therapeutics Shares Surge 37% on Promising KT-621 Trial Results

    Kymera Therapeutics Shares Surge 37% on Promising KT-621 Trial Results

    Kymera Therapeutics Inc. (NASDAQ:KYMR) saw its stock jump 37.3% in premarket trading after the company announced strong Phase 1 trial results for KT-621, its oral STAT6 degrader targeting allergic and inflammatory diseases. The trial demonstrated that KT-621 achieved over 90% average STAT6 degradation in blood at doses above 1.5 mg and complete degradation in both…

  • Palantir Stock Hits Record High of $133.55 on Strong Earnings and Expanding Contracts

    Palantir Stock Hits Record High of $133.55 on Strong Earnings and Expanding Contracts

    Palantir Technologies Inc. (NASDAQ:PLTR) surged to an all-time high of $133.55, driven by exceptional earnings and sustained growth in both government and commercial sectors. The stock’s meteoric rise has pushed the company’s market capitalization to $311 billion, underscoring investor confidence in Palantir’s expanding role in the data analytics and AI ecosystem. The stock is up…

  • CAE Appoints Northrop Grumman Executive Matthew Bromberg as New CEO

    CAE Appoints Northrop Grumman Executive Matthew Bromberg as New CEO

    CAE Inc. (NYSE:CAE), the Canadian aviation and defense technology company, has named Matthew Bromberg as its next chief executive officer. Currently a senior executive at Northrop Grumman (NYSE:NOC), Bromberg will officially assume the role on August 13, taking over from Marc Parent, who has led CAE since 2009 and announced his planned departure in November.…

  • Amazon’s Pricing Tools Face Antitrust Scrutiny in Germany

    Amazon’s Pricing Tools Face Antitrust Scrutiny in Germany

    German competition authorities are scrutinizing Amazon’s (NASDAQ:AMZN) pricing tools, citing concerns that the mechanisms could breach competition laws. The Federal Cartel Office raised issues with how Amazon’s marketplace algorithms highlight competitively priced products while potentially downranking or removing listings deemed too expensive. Amazon operates a vast marketplace featuring products from both third-party sellers and the…

  • Blueprint Medicines Stock Surges as Sanofi Announces $9.5 Billion Acquisition

    Blueprint Medicines Stock Surges as Sanofi Announces $9.5 Billion Acquisition

    Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) soared 26.5% after Sanofi (NASDAQ:SNY) revealed plans to acquire the biopharmaceutical company in a deal valued at approximately $9.5 billion. The acquisition strengthens Sanofi’s rare disease and immunology portfolio, while adding a promising pipeline of early-stage immunology assets. Under the terms of the agreement, Sanofi will pay $129.00 per…

  • Alphabet Shares Dip Amid Uncertainty Over Antitrust Case

    Alphabet Shares Dip Amid Uncertainty Over Antitrust Case

    Shares of Alphabet Inc. (NASDAQ:GOOGL) dropped 2% as uncertainty lingers over the outcome of a high-profile federal antitrust trial. During a recent hearing, U.S. District Judge Amit Mehta suggested he may consider less drastic measures than those proposed by the Department of Justice (DOJ) to curb Google’s dominance in online search and advertising. The judge…

  • Liquidia Shares Climb After First Commercial Shipment of YUTREPIA

    Liquidia Shares Climb After First Commercial Shipment of YUTREPIA

    Liquidia Technologies Inc (NASDAQ:LQDA) saw its shares rise nearly 10% following news that it will begin its initial commercial shipments of YUTREPIA™ (treprostinil) inhalation powder. This milestone follows FDA approval granted on May 23, 2025, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD). The product will…